Similarly, 1,1’-([1,1’-biphenyl]-4,4’-diyl)bis(3-(piperidin-1-yl)propan-1-one)dihydrochloride (DL0410), a novel synthetic dual AChE/butyrylcholinesterase (BuChE) inhibitor for AD treatment, showed multitarget properties for AD treatment, such as improving cognitive deficits, enhancing synapse loss, inhibiting the activity of cholinesterase and reversing the plaque load caused by Aβ [98-100]. The gene discussed is BCHE; the disease is Alzheimer disease.